Premium
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study *
Author(s) -
Kayser Sabine,
Hills Robert K.,
Langova Ralitsa,
Kramer Michael,
Guijarro Francesca,
Sustkova Zuzana,
Estey Elihu H.,
Shaw Carole M.,
Ráčil Zdeněk,
Mayer Jiri,
Zak Pavel,
Baer Maria R.,
Brunner Andrew M.,
Szotkowski Tomas,
Cetkovsky Petr,
Grimwade David,
Walter Roland B.,
Burnett Alan K.,
Ho Anthony D.,
Ehninger Gerhard,
MüllerTidow Carsten,
Platzbecker Uwe,
Thiede Christian,
Röllig Christoph,
Schulz Angela,
Warsow Gregor,
Brors Benedikt,
Esteve Jordi,
Russell Nigel H.,
Schlenk Richard F.,
Levis Mark J.
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17336
Subject(s) - medicine , busulfan , chemotherapy , karyotype , transplantation , oncology , cytogenetics , myeloid leukemia , hematopoietic stem cell transplantation , gastroenterology , chromosome , biology , genetics , gene
Summary In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/ MYST3–CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16–75) years. AML was de novo in 58%, therapy‐related (t‐AML) in 37% and secondary after myelodysplastic syndrome (s‐AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3–CREBBP , whole‐genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1 , BRD3 , FLT3 , MLH1 , POLG , TP53 , SAMD4B ( n = 3, each), EYS , KRTAP9‐1 SPTBN5 ( n = 4, each), RUNX1 and TET2 ( n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow‐up was 5·48 years; five‐year survival rate was 17%. Patients with s‐/t‐AML ( P = 0·01) and those with complex karyotype ( P = 0·04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo‐HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo‐HCT in CR1 significantly improved survival ( P = 0·04); multivariable analysis revealed that allo‐HCT in CR1 was effective in de novo AML but not in patients with s‐AML/t‐AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo‐HCT performed in CR1.